Skip to Content


In the US, Idursulfase (idursulfase systemic) is a member of the drug class lysosomal enzymes and is used to treat Mucopolysaccharidosis Type II.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Treatment of mucopolysaccharidosis II (Hunter syndrome)

Chemical Names

α-L-iduronate sulfate sulfatase (WHO)

Sulfatase, L-idurono- (USAN)

Foreign Names

  • Idursulfaseum (Latin)
  • Idursulfase (German)
  • Idursulfase (French)
  • Idursulfasa (Spanish)

Generic Names

Brand Names

  • Elaprase
    DRAC, Switzerland; Genzyme Japan, Japan; Paladin, Canada; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, New Zealand; Serono Europe, Lithuania; Shire, Belgium; Shire, Czech Republic; Shire, Spain; Shire, Greece; Shire, Israel; Shire, Italy; Shire, Netherlands; Shire, Norway; Shire, Romania; Shire, Taiwan; Shire HGT, Germany; Shire HGT, Denmark; Shire HGT, Sweden; Shire Human Genetic Therapies, Hungary; Shire Human Genetic Therapies AB, Portugal; Solpharm, Croatia (Hrvatska)

International Drug Name Search


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.